Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta's Q4, FY 2015 Revenues Rise on PersonalizeDx Acquisition

NEW YORK (GenomeWeb) – Rosetta Genomics announced after the close of the market Wednesday a more than 400 percent jump in fourth quarter revenues as the company benefitted from an expanded suite of molecular diagnostic offerings.

For the three-month period ended Dec. 31, Rosetta's revenues climbed to $3.6 million, including $1.6 million in license revenue, from $698,000, which included $228,000 in license revenue, in the same period a year ago.

"We set out to broaden our differentiated and proprietary content for use in personalized medicine, and while we entered 2015 with nearly all our revenue coming from a single commercial assay, we exited 2015 with more than 20 individual test offerings contributing to our top line," Rosetta President and CEO Kenneth Berlin said in a statement.

Revenues from solid tumor testing services, including the microRNA-based Cancer Origin Test, rose to $726,000 in the quarter from $343,000 in Q4 2014. Meanwhile, the company's urologic cancer testing services operations, where were acquired through Rosetta's purchase of PersonalizeDx last year, generated $1.2 million in revenues.

Rosetta's fourth quarter net loss was $6.7 million, or $.37 a share, and included $1.6 million in expenses related to the revaluation of warrants for share purchase agreements. The firm did not provide a comparison to the bottom line for the fourth quarter of 2014.

Fourth quarter research and development costs were $1 million, while SG&A expenses were $3.6 million. Rosetta said that it does not believe prior-year comparisons are meaningful as they would not reflect the impact of PersonalizeDx operations.

For full-year 2015, Rosetta's revenues from continuing operations jumped to $8.3 million from $1.3 million. Revenues from solid tumor testing increased 227 percent to $3.2 million, while revenues from urologic testing were $3.5 million.

The company's 2015 net loss was $17.3 million, or $1.15 a share, compared with $14.5 million, or $1.29 a share, in 2014. On a non-GAAP basis, its net loss for FY 2015 was $.99 per share versus an adjusted loss of $1.22 per share for 2014.

Its R&D spending for the year increased to $3 million from $1.9 million, primarily due to the costs associated with the development of its thyroid cancer assay. Meantime, SG&A expenses for the year rose to $14.9 million from $12.3 million, an increase the firm attributed to the PersonalizeDx acquisition.

At the end of 2015, Rosetta had cash, cash equivalents, restricted cash, and short-term bank deposits totaling $13.5 million. This figure doe not include $1.6 million in licensing revenues received in January related to a deal inked in December 2015.Rosetta said it expects it cash position will fund its operations for at least the next 12 months.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.